MX2007004079A - Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento. - Google Patents

Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.

Info

Publication number
MX2007004079A
MX2007004079A MX2007004079A MX2007004079A MX2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A MX 2007004079 A MX2007004079 A MX 2007004079A
Authority
MX
Mexico
Prior art keywords
cancer cells
treatment
neu
detection
elevated levels
Prior art date
Application number
MX2007004079A
Other languages
English (en)
Inventor
Robert M Lorence
Ming Lu
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of MX2007004079A publication Critical patent/MX2007004079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La expresion de la proteina Her-2/neu en celulas cancerosas circulantes en una muestra de sangre es detectada por el aislamiento de las celulas cancerosas de la muestra de sangre y luego la realizacion en las celulas cancerosas aisladas de un inmunoensayo de Her-2/neu sensible. Un resultado positivo indica la expresion de Her- 2/neu en celulas cancerosas en la muestra de sangre. Este metodo se puede utilizar para identificar a pacientes con cancer quienes es probable que se beneficien del tratamiento con un agente carcinostatico que fija como objetivo la Her-2/neu, tal como trastuzumab (HERCEPTINA).
MX2007004079A 2004-10-06 2005-10-06 Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento. MX2007004079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61633204P 2004-10-06 2004-10-06
PCT/US2005/035894 WO2006041959A2 (en) 2004-10-06 2005-10-06 Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment

Publications (1)

Publication Number Publication Date
MX2007004079A true MX2007004079A (es) 2007-06-15

Family

ID=36148887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004079A MX2007004079A (es) 2004-10-06 2005-10-06 Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.

Country Status (10)

Country Link
US (2) US20080261243A1 (es)
EP (1) EP1797431B1 (es)
JP (1) JP4798801B2 (es)
CN (1) CN101036055B (es)
AT (1) ATE497165T1 (es)
CA (1) CA2582713A1 (es)
DE (1) DE602005026143D1 (es)
HK (1) HK1103439A1 (es)
MX (1) MX2007004079A (es)
WO (1) WO2006041959A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005034628B4 (de) * 2005-07-19 2007-08-23 Epigenomics Ag Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA
EP1803822A1 (en) * 2005-12-30 2007-07-04 Adnagen AG Method for the individual characterization of therapeutic target molecules and use thereof
MX2008013331A (es) * 2006-04-18 2008-11-10 Wellstat Biologics Corp Deteccion de receptores de esteroides en celulas de carcinoma circulantes y tratamiento.
WO2007121465A2 (en) 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells
CA2646497A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of circulating endothelial cells
US20080200342A1 (en) 2007-02-15 2008-08-21 Rao Rupa S Device, Array, And Methods For Disease Detection And Analysis
JP2010525326A (ja) * 2007-04-19 2010-07-22 ウェルスタット バイオロジックス コーポレイション 分離されていない循環癌細胞由来のＨｅｒ−２／ｎｅｕタンパク質の上昇したレベルの検出および治療
KR100972618B1 (ko) * 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
JP5040597B2 (ja) * 2007-11-06 2012-10-03 日本電気株式会社 評価システム、評価方法および評価プログラム
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
MX2011004467A (es) 2008-10-31 2011-07-28 Biogen Idec Inc Moleculas de objetivo light y usos de las mismas.
WO2010070117A1 (en) * 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
CN101880650B (zh) * 2009-05-04 2013-01-16 卢焕梅 一种从外周血中快速提取循环的非血缘性有核细胞的组合物和试剂盒及其应用
AU2011274789B2 (en) * 2010-07-07 2014-04-10 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
FR2976294B1 (fr) 2011-06-10 2018-02-16 Universite De Nice Sophia Antipolis Methode de prediction de la reponse a un traitement avec un agent bloquant her2
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
CN104561246B (zh) * 2013-10-18 2018-06-15 深圳先进技术研究院 血液中循环癌细胞的检测信号放大的方法与试剂盒
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
CN104458710B (zh) * 2014-12-09 2017-11-14 山东省海盟生化科技有限公司 肿瘤早期高通量电化学发光检测方法的构建
CN106932583A (zh) * 2015-12-29 2017-07-07 北京大成生物工程有限公司 人表皮生长因子受体Her-2/neu定量检测试剂盒及其制备方法与应用
CN106226374B (zh) * 2016-08-18 2018-10-16 中南大学 一种人类表皮生长因子受体-2浓度的检测方法
CN106319069B (zh) * 2016-09-28 2020-02-14 河南乾坤科技有限公司 一种精确测定病源细胞的试剂盒及其应用
CN111257310B (zh) * 2020-03-10 2023-05-02 莆田学院附属医院（莆田市第二医院） 一种用于癌细胞识别的电致化学发光传感器的制备方法
CN117074692B (zh) * 2023-08-15 2024-04-09 复旦大学附属华山医院 一种关于脑脊液中肿瘤细胞her2抗原表达生物信息的识别方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
CA2223027A1 (en) * 1995-06-07 1996-12-19 Igen, Inc. Electrochemiluminescent enzyme immunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
KR100399475B1 (ko) * 1998-02-12 2003-09-29 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 순환 중인 암세포의 신속하고 효과적인 분리 방법 및 이를위한 제제
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
CA2391450A1 (en) * 1999-11-15 2001-05-25 University Of Southern California Targeted delivery of therapeutic and diagnostic moieties
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
KR20030080002A (ko) * 2001-02-16 2003-10-10 이뮤니베스트 코포레이션 순환 암 세포를 신속하고 효과적으로 분리하기 위한 방법및 시약
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
US6949355B2 (en) * 2001-10-11 2005-09-27 Aviva Biosciences Methods, compositions, and automated systems for separating rare cells from fluid samples
PT2263691E (pt) * 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
MX2008013331A (es) * 2006-04-18 2008-11-10 Wellstat Biologics Corp Deteccion de receptores de esteroides en celulas de carcinoma circulantes y tratamiento.
CA2646497A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of circulating endothelial cells
WO2007121465A2 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells

Also Published As

Publication number Publication date
HK1103439A1 (en) 2007-12-21
US20080261243A1 (en) 2008-10-23
EP1797431A2 (en) 2007-06-20
WO2006041959A2 (en) 2006-04-20
WO2006041959A3 (en) 2006-06-15
CN101036055A (zh) 2007-09-12
CN101036055B (zh) 2011-06-29
ATE497165T1 (de) 2011-02-15
WO2006041959A8 (en) 2008-01-31
JP2008517253A (ja) 2008-05-22
US20110070598A1 (en) 2011-03-24
CA2582713A1 (en) 2006-04-20
DE602005026143D1 (de) 2011-03-10
EP1797431B1 (en) 2011-01-26
EP1797431A4 (en) 2008-07-09
JP4798801B2 (ja) 2011-10-19

Similar Documents

Publication Publication Date Title
HK1103439A1 (en) Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
Gao et al. Circulating cell-free DNA for cancer early detection
Chen et al. Indoxyl sulfate enhance the hypermethylation of klotho and promote the process of vascular calcification in chronic kidney disease
Romiti et al. Circulating tumor cells count predicts survival in colorectal cancer patients
NO20050775L (no) Fremgangsmater for identifisering av tumorer som responderer pa behandling med anti-ErbB2-antistoffer
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
NZ616755A (en) Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
WO2009077864A3 (en) Compositions and methods of detecting tiabs
EP2196474A3 (en) Therapeutic targets in cancer
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
WO2016201450A3 (en) Cancer treatment and diagnosis
GB2467467A (en) Taz/wwtr1 for diagnosis and treatment of cancer
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
EP1767647A4 (en) METHOD FOR ASSESSING THE PROPERTIES OF ANIMAL CELL AND CANCER DIAGNOSTIC PROCEDURE
NO20072296L (no) Fremgangsmater og systemer for prognose og behandling av faste tumorer
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
WO2018106625A3 (en) APPARATUS AND METHOD FOR CUSTOMIZING NUTRITION BASED ON BIOSENSOR DATA
WO2008082673A3 (en) Companion diagnostic assays for cancer therapy
Mortensen et al. Quality of life in patients with multiple myeloma: a qualitative study
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도
Mima et al. Advanced age is a risk factor for recurrence after resection in stage II colorectal cancer
WO2008147206A3 (en) Means and methods for classifying samples of multiple sclerosis patients

Legal Events

Date Code Title Description
FG Grant or registration